Medications

Jury orders Gilead to pay Merck $2.5bn in patent case

A US jury has ordered pharmaceutical giant Gilead Sciences to pay $2.5 billion to competitor Merck in a patent infringement case involving a drug used to treat hepatitis C, the two companies said.

Diseases, Conditions, Syndromes

Rare disease gene has a key role in chronic hepatitis C infection

Hepatitis C virus (HCV) hijacks the host's fat metabolism for its own survival, growth, and transport in the human body. A study published on April 28th in PLOS Pathogens identifies a host gene involved in the formation of ...

Diseases, Conditions, Syndromes

Most people with hepatitis C go untreated, despite effective drugs

Just 20 percent of people infected with the hepatitis C virus (HCV) begin the recommended treatment regimen and less than 5 percent go on to successfully overcome the virus, according to a new review in General Hospital Psychiatry. ...

page 6 from 15